Thinking outside the pocket

Insulin-like growth factor-1 receptor, a kinase involved in cell turnover and apoptosis, is seen as a promising cancer target. However, it has been difficult to develop an inhibitor, as IGF-1 receptor is 85% homologous to the insulin receptor which, when knocked out, results in insulin-resistant diabetes. Biovitrum AB now has in-licensed an oral drug candidate that it says can selectively inhibit IGF-1 receptor.

IGF-1 receptor is an important mediator between growth hormone and growth, and researchers believe that it may fuel malignant transformation both directly and by modulating the effects of sex steroids. It has been shown that it stimulates proliferation, prevents apoptosis, and protects cancer cells from chemotherapy. Moreover, it modulates angiogenesis by up-regulating expression of vascular endothelial growth factor (VEGF)...